<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 10-QSB
[X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the Quarter Ended: December 31, 1999
[ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the Transition Period from _____________ to ____________
Commission File Number 0-24641
-------
IMMUNOTECHNOLOGY CORPORATION
----------------------------------------------
(Name of Small Business Issuer in its charter)
Delaware 84-1016435
- ------------------------------- --------------------------
(State or other jurisdiction of (I.R.S. Employer I.D. No.)
incorporation or organization)
1661 Lakeview Circle, Ogden, Utah 84403
------------------------------------------------------
(Address of principal executive offices and Zip Code)
(801) 399-3632
----------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
(1) Yes X No (2) Yes X No
--- --- --- ---
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
Common Stock, Par Value $0.00001 4,884,327
- -------------------------------- ----------------------------
Title of Class Number of Shares Outstanding
as of December 31, 1999
<PAGE>
<PAGE> 2
PART I -- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
IMMUNOTECHNOLOGY CORPORATION
FINANCIAL STATEMENTS
(UNAUDITED)
The financial statements included herein have been prepared by the
Company, without audit, pursuant to the rules and regulations of the
Securities and Exchange Commission. Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted.
However, in the opinion of management, all adjustments (which include only
normal recurring accruals) necessary to present fairly the financial position
and results of operations for the periods presented have been made. These
financial statements should be read in conjunction with the accompanying
notes, and with the historical financial information of the Company.
<PAGE>
<PAGE> 3
IMMUNOTECHNOLOGY CORPORATION
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEET
ASSETS (Unaudited)
December 31, June 30,
1999 1999
----------- -----------
CURRENT ASSETS
Cash $ 337 $ 991
Advance to officer - 3,696
----------- -----------
TOTAL ASSETS $ 337 $ 4,687
=========== ===========
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accrued expenses $ 24,656 $ 24,506
Advances from an officer, note 3 6,287 -
----------- -----------
TOTAL CURRENT LIABILITIES 30,943 24,506
----------- -----------
COMMITMENTS AND CONTINGENCIES, note 5
STOCKHOLDERS' DEFICIT
Preferred stock, par value
$.00001 per share
Authorized - 5,000,000 shares
Issued - none
Common stock, par value
$.00001 per share
Authorized - 50,000,000 shares
Issued and outstanding - 4,884,327 11,617 11,617
Paid in capital 239,163 239,163
Accumulated deficit prior to the development stage (151,332) (151,332)
Accumulated deficit during the development stage (130,054) (119,267)
----------- -----------
TOTAL STOCKHOLDERS' DEFICIT (30,606) (19,819)
----------- -----------
TOTAL LIABILITIES AND
STOCKHOLDERS' DEFICIT $ 337 $ 4,687
=========== ===========
The accompanying notes are an integral part of these financial statements.
<PAGE>
<PAGE> 4
IMMUNOTECHNOLOGY CORPORATION
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
From Inception of
the Development
Three Months Six Months Three Months Six Months Stage, July 1, 1992
ended ended ended ended through
Dec 31, 1999 Dec 31, 1999 Dec 31, 1998 Dec 31, 1998 December 31, 1999
------------ ------------ ------------ ------------ --------------
<S> <C> <C> <C> <C> <C>
REVENUE $ - $ - $ - $ - $ -
COST OF REVENUE - - - - -
------------ ------------ ------------ ------------ --------------
GROSS PROFIT - - - - -
------------ ------------ ------------ ------------ --------------
OPERATING EXPENSES
Professional fees 3,530 8,270 6,766 10,848 82,603
Taxes and licenses - - - 42 1,482
Bank fees and service charges 42 104 42 42 1,823
Meals and entertainment - - - - 300
Travel - 2,000 2,245 2,245 28,418
Office expense 125 280 675 675 7,731
Interest expense 125 133 1,815 3,047 7,697
------------ ------------ ------------ ------------ --------------
TOTAL OPERATING EXPENSES $ 3,822 $ 10,787 $ 11,543 16,899 130,054
------------ ------------ ------------ ------------ --------------
NET LOSS $ (3,822) $ (10,787) $ (11,543) $ (16,899) $ (130,054)
============ ============ ============ ============ ==============
BASIC LOSS PER COMMON
SHARE $ (0.00) $ (0.00) $ (0.01) $ (0.01)
============ ============ ============ ============
WEIGHTED AVERAGE NUMBER
OF COMMON SHARES 4,884,327 4,884,327 1,157,996 1,157,996
============ ============ ============ ============
</TABLE>
The accompanying notes are an integral part of these financial statements
<PAGE>
<PAGE> 5
IMMUNOTECHNOLOGY CORPORATION
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF STOCKHOLDERS' DEFICIT
(Unaudited)
<TABLE>
<CAPTION>
Accumulated
Common Additional Deficit Prior Accumulated
Stock Paid-in to Deficit After
Par Value Capital July 1, 1992 July 1, 1992 Total
------------ ------------ ------------ ------------ ------------
<S> <C> <C> <C> <C> <C>
Balance at July 1, 1992 $ 11,580 $ 122,752 $ (151,332) $ - $ (17,000)
Net Loss from July 1, 1992
through June 30, 1998 - - - (68,926) (68,926)
------------ ------------ ------------ ------------ ------------
Balance at June 30, 1998 11,580 122,752 (151,332) (68,926) (85,926)
Net loss - - - (5,356) (5,356)
------------ ------------ ------------ ------------ ------------
Balance at September 30, 1998 11,580 122,752 (151,332) (74,282) (91,282)
Net loss - - - (11,543) (11,543)
------------ ------------ ------------ ------------ ------------
Balance at December 31, 1998 $ 11,580 $ 122,752 $ (151,332) $ (85,825) $ (102,825)
------------ ------------ ------------ ------------ ------------
Issuance of common stock upon
conversion of debt, note 4 37 116,411 - - 116,448
Net Loss - - - (33,442) (33,442)
------------ ------------ ------------ ------------ ------------
Balance at June 30, 1999 11,617 239,163 (151,332) (119,267) (19,819)
Net Loss - - - (6,965) (6,965)
------------ ------------ ------------ ------------ ------------
Balance at September 30, 1999 11,617 239,163 (151,332) (126,232) (26,784)
------------ ------------ ------------ ------------ ------------
Net Loss - - - (3,822) (3,822)
------------ ------------ ------------ ------------ ------------
Balance at December 31, 19999 $ 11,617 $ 239,163 $ (151,332) $ (130,054) $ (30,606)
============ ============ ============ ============ ============
</TABLE>
The accompanying notes are an integral part of these financial statements
<PAGE>
<PAGE> 6
IMMUNOTECHNOLOGY CORPORATION
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
From Inception of
the Development
Three Months Six Months Three Months Six Months Stage, July 1, 1992
ended ended ended ended through
Dec 31, 1999 Dec 31, 1999 Dec 31, 1998 Dec 31, 1998 December 31, 1999
------------ ------------ ------------ ------------ --------------
<S> <C> <C> <C> <C> <C>
CASH FLOWS FROM OPERATING
ACTIVITIES:
Net loss $ (3,822) $ (10,787) $ (11,543) $ (16,899) $ (130,054)
Adjustment to reconcile net
loss to net cash used in
operating activities
Increase (decrease) in
accrued expenses 125 150 815 (6,808) 14,363
------------ ------------ ------------ ------------ --------------
NET CASH USED IN
OPERATING ACTIVITIES (3,697) (10,637) (10,728) (23,707) (115,691)
------------ ------------ ------------ ------------ --------------
CASH FLOWS FROM INVESTING
ACTIVITIES - - - - -
------------ ------------ ------------ ------------ --------------
CASH FLOWS FROM FINANCING
ACTIVITIES:
Advances from an officer 3,000 9,983 11,350 23,050 108,528
Proceeds from notes payable - - - - 7,500
------------ ------------ ------------ ------------ --------------
NET CASH PROVIDED BY
FINANCING ACTIVITIES 3,000 9,983 11,350 23,050 116,028
------------ ------------ ------------ ------------ --------------
NET INCREASE (DECREASE)
IN CASH (697) (654) 622 (657) 337
CASH AT BEGINNING OF PERIOD 1,034 991 74 1,353 -
------------ ------------ ------------ ------------ --------------
CASH AT END OF PERIOD $ 337 $ 337 $ 696 $ 696 $ 337
============ ============ ============ ============ ==============
Supplementary disclosures:
Interest paid $ - $ 8 $ 1,000 $ 1,000 $ 1,668
============ ============ ============ ============ ==============
</TABLE>
The accompanying notes are an integral part of these financial statements.
<PAGE>
<PAGE> 7
IMMUNOTECHNOLOGY CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization and Going Concern
- ------------------------------
ImmunoTechnology Corporation was incorporated on November 30, 1989 under the
laws of the State of Delaware. ImmunoTechnology Corporation operated a medical
test laboratory until 1992, when it ceased operations. The Company is no
longer operating, and will attempt to locate a new business (operating
company), and offer itself as a merger vehicle for a company that may desire
to go public through a merger rather than through its own public stock
offering.
The accompanying financial statements have been prepared on a going concern
basis, which contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business. As shown in the financial
statements during the quarter ended December 31, 1999, the Company did not
generate any revenue, and has a net capital deficiency. These factors among
other may indicate that the Company will be unable to continue as a going
concern for a reasonable period of time. For the six months ended December 31,
1999, the Company funded its disbursements by loans from an officer.
The financial statements do not include any adjustments relating to the
recoverability of assets and classification of liabilities that might be
necessary should the Company be unable to continue as a going concern.
Cash Flows
- ----------
Cash consists of balances in a demand account at a bank.
Estimates
- ---------
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect certain reported amounts and disclosures. Accordingly, actual
results may differ from those estimates.
Fair Value of Financial Instruments
- -----------------------------------
The carrying amounts of the Company's advances and notes payable approximate
fair value.
2. INCOME TAXES
The Company has loss carryforwards available to offset future taxable income.
The loss carryforwards at December 31, 1999 total approximately $281,404 and
expire between June 30, 2004 and June 30, 2015. Loss carryforwards are limited
in accordance with rules of change in ownership.
3. RELATED PARTY TRANSACTIONS
An officer of the Company advanced money to the Company. At March 31, 1999,
the advances and related accrued interest were converted into shares of common
stock (see Note 4). During the quarter ended September 30, 1999, the officer
repaid $3,696 that the Company had loaned to him, and advanced $3,287 to the
Company. During the quarter ended December 31, 1999, the officer advanced an
additional $3,000 to the Company. All advances bear interest at a rate of 10%
and are due on demand.
<PAGE> 8
IMMUNOTECHNOLOGY CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
4. COMMON STOCK
On March 31, 1999, the Company converted its advances from the officer, notes
payable to minority shareholders and related accrued interest totaling
$116,448 into 3,726,331 shares of common stock or $0.03125 per share.
5. COMMITMENTS AND CONTINGENCIES
The Company accrued $17,000 for legal services performed prior to the
development stage. Should this balance accrue interest, the liability could
increase by approximately $15,000.
<PAGE>
<PAGE> 9
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
General
- -------
The Registrant was incorporated on November 30, 1989, in the state of
Delaware. The Registrant's predecessor was LJC Corporation, a Utah
corporation, organized on November 8, 1984 ("LJC"). On October 7, 1989, LJC
acquired ImmunoTechnology Laboratories, Inc., a Colorado corporation
("ITL"),by means of a stock-for-stock exchange with the shareholder of ITL. As
a result of this transaction, ITL became a wholly owned subsidiary of LJC. On
October 10, 1989, LJC changed its name to ImmunoTechnology Laboratories, Inc.
("ITL-UT").
At a special meeting of the shareholders of ITL-UT, the shareholders approved
a proposal to redomicile ITL-UT in the state of Delaware, by forming a
Delaware corporation and merging ITL-UT into the Delaware corporation, and
changing the its name to ImmunoTechnology Corporation. The merger was
effective on December 21, 1989. As a result of the merger, ITL-UT no longer
exists.
ITL was formed for the purpose of engaging in the business of operating a
medical test related laboratory. The Registrant's only business has been the
operation of ITL, whose operations were discontinued in 1992.
Since discontinuing operations in 1992 the Registrant has had no operations is
now seeking potential business acquisition or opportunities to enter in an
effort to commence business operations. The Registrant does not propose to
restrict its search for a business opportunity to any particular industry or
geographical area and may, therefore, engage in essentially any business in
any industry. The Registrant has unrestricted discretion in seeking and
participating in a business opportunity, subject to the availability of such
opportunities, economic conditions, and other factors.
The selection of a business opportunity in which to participate is complex and
risky. Additionally, as the Registrant has only limited resources, it may be
difficult to find good opportunities. There can be no assurance that the
Registrant will be able to identify and acquire any business opportunity which
will ultimately prove to be beneficial to the Registrant and its shareholders.
The Registrant will select any potential business opportunity based on
management's business judgment.
The activities of the Registrant are subject to several significant risks
which arise primarily as a result of the fact that the Registrant has no
specific business and may acquire or participate in a business opportunity
based on the decision of management which potentially could act without the
consent, vote, or approval of the Registrant's shareholders. Because of the
Registrant's current status having no assets and no recent operating history,
in the event the Registrant does successfully acquire or merge with an
operating business opportunity, it is likely that the Registrant's present
shareholders will experience substantial dilution and there will be a probable
change in control of the Registrant.
The Registrant has voluntarily filed its registration statement on Form
10SB in order to make information concerning itself more readily available to
the public. Management believes that being a reporting company under the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), could
provide a prospective merger or acquisition candidate with additional
<PAGE>
<PAGE> 10
information concerning the Registrant. In addition, management believes that
this might make the Registrant more attractive to an operating business
opportunity as a potential business combination candidate. As a result of
filing its registration statement, the Registrant is obligated to file with
the Commission certain interim and periodic reports including an annual report
containing audited financial statements. The Registrant intends to continue
to voluntarily file these periodic reports under the Exchange Act even if its
obligation to file such reports is suspended under applicable provisions of
the Exchange Act.
Any target acquisition or merger candidate of the Registrant will become
subject to the same reporting requirements as the Registrant upon consummation
of any such business combination. Thus, in the event that the Registrant
successfully completes an acquisition or merger with another operating
business, the resulting combined business must provide audited financial
statements for at least the two most recent fiscal years or, in the event that
the combined operating business has been in business less than two years,
audited financial statements will be required from the period of inception of
the target acquisition or merger candidate.
Sources of Business Opportunities
- ---------------------------------
The Registrant intends to use various sources in its search for potential
business opportunities including its officers and directors, consultants,
special advisors, securities broker-dealers, venture capitalists, members of
the financial community and others who may present management with unsolicited
proposals. Because of the Registrant's lack of capital, it may not be able to
retain on a fee basis professional firms specializing in business acquisitions
and reorganizations. Rather, the Registrant will most likely have to rely on
outside sources, not otherwise associated with the Registrant, that will
accept their compensation only after the Registrant has finalized a successful
acquisition or merger. To date, the Registrant has not engaged nor entered
into any discussions, negotiations, agreements nor understandings regarding
retention of any consultant to assist the Registrant in its search for
business opportunities, nor is management presently in a position to actively
seek or retain any prospective consultants for these purposes.
The Registrant does not intend to restrict its search to any specific
kind of industry or business. The Registrant may investigate and ultimately
acquire a venture that is in its preliminary or development stage, is already
in operation, or in various stages of its corporate existence and development.
Management cannot predict at this time the status or nature of any venture in
which the Registrant may participate. A potential venture might need
additional capital or merely desire to have its shares publicly traded. The
most likely scenario for a possible business arrangement would involve the
acquisition of, or merger with, an operating business that does not need
additional capital, but which merely desires to establish a public trading
market for its shares. Management believes that the Registrant could provide a
potential public vehicle for a private entity interested in becoming a
publicly held corporation without the time and expense typically associated
with an initial public offering.
The investigation of specific business opportunities and the negotiation,
drafting, and execution of relevant agreements, disclosure documents, and
other instruments will require management time and attention and will require
the Company to incur costs for payment of accountants, attorneys, and others.
If a decision is made not to participate in or complete the acquisition of a
<PAGE>
<PAGE> 11
specific business opportunity, the costs incurred in a related investigation
will not be recoverable. Further, even if agreement is reached for the
participation in a specific business opportunity by way of investment or
otherwise, the failure to consummate the particular transaction may result in
the loss to the Company of all related costs incurred.
Currently, management is not able to determine the time or resources that
will be necessary to complete the participation in or acquisition of any
future business prospect. There is no assurance that the Company will be able
to acquire an interest in any such prospects, products or opportunities that
may exist or that any activity of the Company, regardless of the completion of
any participation in or the acquisition of any business prospect, will be
profitable.
Liquidity and Capital Resources
- -------------------------------
Although the Company has had only limited expenses, it may have to incur
additional legal and accounting costs to remain current on its financial and
corporate reporting obligations. Management anticipates that the Company will
incur more cost including legal and accounting fees to locate and complete a
merger or acquisition. At the present time the Company does not have the
assets to meet these financial requirements.
At December 31, 1999, the Company had assets of $337 in cash and liabilities
of $30,943. The Company had a working capital deficit at December 31, 1999 of
$(30,606). The Company has only incidental ongoing expenses primarily
associated with maintaining its corporate status and professional fees
associated with accounting and legal costs.
An officer of the Company has advanced money to the Company for time to time
and such advances are bearing interest at a rate of 10% and have no maturity
date. The amount of the advance for expenses in the six month period ending
December 31, 1999 has been $6,287.
The president of the Company is providing the Company with a location for its
offices on a "rent free basis" and no salaries or other form of compensation
are being paid by the Company for the time and effort required by management
to run the Company. The Company does intend to reimburse its officers and
directors for out of pocket cost.
Results of Operations
- ---------------------
Since discontinuing operations in 1992, the Company has not generated revenue
and it is unlikely that any revenue will be generated until the Company
locates a business opportunity with which to acquire or merge. For the three
and six month periods ended December 31, 1998, the Company has incurred $3,530
and $8,270, respectively, in general and administrative expenses. The
Company incurred an accumulated deficit of $(151,332) prior to July 1, 1992
(inception of the development stage) and has an accumulated deficit of
$(30,606)after inception of the development stage.
<PAGE>
<PAGE> 12
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 2. CHANGES IN SECURITIES
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
ITEM 5. OTHER INFORMATION
None.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits.
---------
No exhibits are included as they are either not required or not
applicable.
(b) Reports on Form 8-K.
--------------------
None.
SIGNATURES
- ----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IMMUNOTECHNOLOGY CORPORATION
[Registrant]
Dated: March 6, 2000 By/S/John A. Wise, President and
Director
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> JUN-30-2000
<PERIOD-END> DEC-31-2000
<CASH> 337
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 337
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 337
<CURRENT-LIABILITIES> 30,943
<BONDS> 0
0
0
<COMMON> 250,780
<OTHER-SE> (281,386)
<TOTAL-LIABILITY-AND-EQUITY> 337
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 10,787
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 133
<INCOME-PRETAX> (10,787)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (10,787)
<EPS-BASIC> (0.00)
<EPS-DILUTED> (0.00)
</TABLE>
